

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

23 May 2025

The Manager Companies
ASX Limited
20 Bridge Street
SYDNEY NSW 2000

Dear Shareholders,

BIOTRON INVESTOR WEBINAR

Investor Webinar | 11 AM AEST – Tue, 27 May 2025

You are invited to register using this link:

https://us06web.zoom.us/webinar/register/WN_4l0Hy82XTKy7THiviHZj-A


Participants may submit questions during registration or during the session

Biotron Limited (ASX: BIT) CEO and Managing Director Dr Michelle Miller and Chairman Mr Michael Hoy will conduct an **Investor Webinar** at 11 AM AEST Tuesday 27 May 2025 to update shareholders on Biotron's latest developments and commercial trajectory.

Previous updates:

- **Successfully Raised \$1.2m** (before costs) in April 2025 enabling the Company to continue commercialisation priorities including the endeavour to achieve strategic partnership(s) for the antiviral programs.
- **BIT225-010 HIV-1 Phase 2 Clinical Trials Met Primary Objectives:**
 - BIT-225 was safe and generally well tolerated with no deaths or drug-related adverse events.
 - BIT225 treated cleared virus faster than those on ART alone.
 - BIT225 induced statistically significant changes in specific immune cell populations, markers and cytokines.
- **Progress in Early-Stage Programs** – Advances in **Hepatitis B and Dengue Virus** programs reinforce Biotron's potential across multiple infectious diseases.
- **Commercialisation Strategy** – Ongoing collaboration with **US-based C14 Consulting Group** to assist the commercialisation objectives.

Yours sincerely



Marcelo Mora
Company Secretary

pjn12633